Latest Breaking News On - Inflammatory bowel diseases - Page 11 : vimarsana.com

Microbiome Market to Witness Stunning Growth by 2030

Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant

Roche will gain the rights to develop, manufacture and commercialize RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseasesRVT-3101 is a.

Roche buys Telavant Holdings for $7.1 billion

ZURICH/FRANKFURT (Reuters) -Roche on Monday said it will buy Telavant, a developer of a new treatment for inflammatory bowel diseases, for an initial $7.1 billion from U.S biotech firm Roivant Holdings and Pfizer Inc. Under the deal, which continues Roche's drive to diversify away from its aging cancer treatment business, the Swiss drugmaker will gain the right to develop, manufacture and commercialise an experimental drug known as RVT-3101, in the U.S. and Japan. New Roche CEO Thomas Schinecker is keen to restore Roche's battered drug development record after major late-stage trial setbacks in the areas of Alzheimer's and cancer immunotherapy last year.

Roche buys Roivant's bowel disease drug for $7.1 billion

ZURICH/FRANKFURT (Reuters) -Roche on Monday said it will buy Telavant, a developer of a new treatment for inflammatory bowel diseases, for an initial $7.1 billion from U.S biotech firm Roivant Holdings and Pfizer Inc. Under the deal, which continues Roche's drive to diversify away from its aging cancer treatment business, the Swiss drugmaker will gain the right to develop, manufacture and commercialise an experimental drug known as RVT-3101, in the U.S. and Japan. New Roche CEO Thomas Schinecker

IBD Linked to Increased Risk of Cerebrovascular Accidents